Kairos Pharma, Ltd. (KAPA)

NYSEAMERICAN: KAPA · Real-Time Price · USD

0.350

-0.025 (-6.62%)

At close: Jun 26, 2026, 4:00 PM EDT

0.350

0.00 (0.00%)

After-hours: Jun 26, 2026, 8:00 PM EDT

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $7.49 million. The enterprise value is $3.50 million.

Market Cap	7.49M
Enterprise Value	3.50M

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 21.41 million shares outstanding. The number of shares has increased by 55.40% in one year.

Current Share Class	21.41M
Shares Outstanding	21.41M
Shares Change (YoY)	+55.40%
Shares Change (QoQ)	+0.78%
Owned by Insiders (%)	31.85%
Owned by Institutions (%)	6.94%
Float	13.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.51
P/TBV Ratio	1.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.31

Current Ratio	10.31
Quick Ratio	8.53
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -93.84% and return on invested capital (ROIC) is -60.22%.

Return on Equity (ROE)	-93.84%
Return on Assets (ROA)	-54.78%
Return on Invested Capital (ROIC)	-60.22%
Return on Capital Employed (ROCE)	-112.86%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.46M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-44.53%
50-Day Moving Average	0.51
200-Day Moving Average	0.77
Relative Strength Index (RSI)	24.62
Average Volume (20 Days)	129,744

Short Selling Information

The latest short interest is 157,342, so 0.73% of the outstanding shares have been sold short.

Short Interest	157,342
Short Previous Month	125,693
Short % of Shares Out	0.73%
Short % of Float	1.17%
Short Ratio (days to cover)	0.88

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.00M
Pretax Income	-5.84M
Net Income	-5.84M
EBITDA	-5.84M
EBIT	-6.00M
Earnings Per Share (EPS)	-$0.30

Full Income Statement

Balance Sheet

The company has $3.68 million in cash and n/a in debt, giving a net cash position of $3.68 million or $0.17 per share.

Cash & Cash Equivalents	3.68M
Total Debt	n/a
Net Cash	3.68M
Net Cash Per Share	$0.17
Equity (Book Value)	5.31M
Book Value Per Share	0.25
Working Capital	4.01M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-3.76M
Capital Expenditures	n/a
Depreciation & Amortization	160,000
Net Borrowing	3.60M
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-55.40%
Shareholder Yield	-55.40%
Earnings Yield	-81.33%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $8.00, which is 2,185.71% higher than the current price. The consensus rating is "Buy".

Price Target	$8.00
Price Target Difference	2,185.71%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2